{"id":"https://openalex.org/W1968370199","doi":"https://doi.org/10.1097/00001813-199808000-00006","title":"Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients","display_name":"Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients","publication_year":1998,"publication_date":"1998-08-01","ids":{"openalex":"https://openalex.org/W1968370199","doi":"https://doi.org/10.1097/00001813-199808000-00006","mag":"1968370199","pmid":"https://pubmed.ncbi.nlm.nih.gov/9773805"},"language":"en","primary_location":{"id":"doi:10.1097/00001813-199808000-00006","doi":"https://doi.org/10.1097/00001813-199808000-00006","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00001813-199808000-00006","pdf_url":null,"source":{"id":"https://openalex.org/S158028025","display_name":"Anti-Cancer Drugs","issn_l":"0959-4973","issn":["0959-4973","1473-5741"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Drugs","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5078629724","display_name":"Mark A. Socinski","orcid":"https://orcid.org/0000-0003-2915-9325","observed_orcids":["https://orcid.org/0000-0003-2915-9325","https://orcid.org/0000-0002-8213-0137"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark A Socinski","raw_affiliation_strings":["Department of Medicine and Pharmacy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill 27599, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine and Pharmacy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill 27599, USA","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5078893992","display_name":"Paul N. Mudd","orcid":"https://orcid.org/0000-0002-9667-8953","observed_orcids":["https://orcid.org/0000-0002-9667-8953"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul N Mudd","raw_affiliation_strings":["Multidisciplinary Thoracic Oncology Program, Divisions of Hematology/Oncology and Pharmaceutics, Department of Medicine and Pharmacy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA","University of North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Multidisciplinary Thoracic Oncology Program, Divisions of Hematology/Oncology and Pharmaceutics, Department of Medicine and Pharmacy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]},{"raw_affiliation_string":"University of North Carolina","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112280099","display_name":"Kristine M. Radomski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kristine M Radomski","raw_affiliation_strings":["Multidisciplinary Thoracic Oncology Program, Divisions of Hematology/Oncology and Pharmaceutics, Department of Medicine and Pharmacy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA","University of North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Multidisciplinary Thoracic Oncology Program, Divisions of Hematology/Oncology and Pharmaceutics, Department of Medicine and Pharmacy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]},{"raw_affiliation_string":"University of North Carolina","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032418111","display_name":"Ann Steagall","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ann Steagall","raw_affiliation_strings":["Multidisciplinary Thoracic Oncology Program, Divisions of Hematology/Oncology and Pharmaceutics, Department of Medicine and Pharmacy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA","University of North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Multidisciplinary Thoracic Oncology Program, Divisions of Hematology/Oncology and Pharmaceutics, Department of Medicine and Pharmacy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]},{"raw_affiliation_string":"University of North Carolina","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111528184","display_name":"Pam Lawrence","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pam Lawrence","raw_affiliation_strings":["Multidisciplinary Thoracic Oncology Program, Divisions of Hematology/Oncology and Pharmaceutics, Department of Medicine and Pharmacy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA","University of North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Multidisciplinary Thoracic Oncology Program, Divisions of Hematology/Oncology and Pharmaceutics, Department of Medicine and Pharmacy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]},{"raw_affiliation_string":"University of North Carolina","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004968749","display_name":"Stephen A. Bernard","orcid":"https://orcid.org/0000-0001-7688-9852","observed_orcids":["https://orcid.org/0000-0001-7688-9852"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen Bernard","raw_affiliation_strings":["Multidisciplinary Thoracic Oncology Program, Divisions of Hematology/Oncology and Pharmaceutics, Department of Medicine and Pharmacy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA","Oncology"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Multidisciplinary Thoracic Oncology Program, Divisions of Hematology/Oncology and Pharmaceutics, Department of Medicine and Pharmacy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]},{"raw_affiliation_string":"Oncology","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025624246","display_name":"Stephen P. Letrent","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stephen P Letrent","raw_affiliation_strings":["Multidisciplinary Thoracic Oncology Program, Divisions of Hematology/Oncology and Pharmaceutics, Department of Medicine and Pharmacy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA","University of North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Multidisciplinary Thoracic Oncology Program, Divisions of Hematology/Oncology and Pharmaceutics, Department of Medicine and Pharmacy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]},{"raw_affiliation_string":"University of North Carolina","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109081729","display_name":"Pablo Gonzalez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pablo Gonzalez","raw_affiliation_strings":["Multidisciplinary Thoracic Oncology Program, Divisions of Hematology/Oncology and Pharmaceutics, Department of Medicine and Pharmacy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA","University of North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Multidisciplinary Thoracic Oncology Program, Divisions of Hematology/Oncology and Pharmaceutics, Department of Medicine and Pharmacy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]},{"raw_affiliation_string":"University of North Carolina","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5056589677","display_name":"Kim L. R. Brouwer","orcid":"https://orcid.org/0000-0003-1945-4929","observed_orcids":["https://orcid.org/0000-0003-1945-4929"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I4390039329","display_name":"UNC Lineberger Comprehensive Cancer Center","ror":"https://ror.org/043ehm030","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kim LR Brouwer","raw_affiliation_strings":["Multidisciplinary Thoracic Oncology Program, Divisions of Hematology/Oncology and Pharmaceutics, Department of Medicine and Pharmacy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA","Pharmacy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Multidisciplinary Thoracic Oncology Program, Divisions of Hematology/Oncology and Pharmaceutics, Department of Medicine and Pharmacy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I4390039329"]},{"raw_affiliation_string":"Pharmacy","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.2923,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":{"value":0.57906622,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"9","issue":"7","first_page":"611","last_page":"619"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11845","display_name":"Cancer therapeutics and mechanisms","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12172","display_name":"Neutropenia and Cancer Infections","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.9980000257492065},{"id":"https://openalex.org/keywords/filgrastim","display_name":"filgrastim","score":0.8259999752044678},{"id":"https://openalex.org/keywords/prolonged-infusion","display_name":"prolonged infusion","score":0.5950000286102295},{"id":"https://openalex.org/keywords/refractory-solid-tumors","display_name":"refractory solid tumors","score":0.9350000023841858},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8029999732971191},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9509999752044678},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9020000100135803},{"id":"https://openalex.org/keywords/steady-state-drug-concentration","display_name":"steady-state drug concentration","score":0.8320000171661377},{"id":"https://openalex.org/keywords/granulocytopenia","display_name":"granulocytopenia","score":0.800000011920929},{"id":"https://openalex.org/keywords/mucositis","display_name":"mucositis","score":0.921999990940094},{"id":"https://openalex.org/keywords/liver-metastases","display_name":"liver metastasis","score":0.8489999771118164},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8610000014305115},{"id":"https://openalex.org/keywords/small-cell-lung-cancer","display_name":"small cell lung cancer","score":0.9990000128746033},{"id":"https://openalex.org/keywords/melanoma","display_name":"melanoma","score":0.8539999723434448},{"id":"https://openalex.org/keywords/chemotherapy-toxicity","display_name":"chemotherapy toxicity","score":0.5509999990463257}],"concepts":[{"id":"https://openalex.org/C2779171977","wikidata":"https://www.wikidata.org/wiki/Q3151081","display_name":"Filgrastim","level":4,"score":0.8703703880310059},{"id":"https://openalex.org/C142424586","wikidata":"https://www.wikidata.org/wiki/Q7307572","display_name":"Refractory (planetary science)","level":2,"score":0.740767776966095},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.7214414477348328},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5575425624847412},{"id":"https://openalex.org/C44280652","wikidata":"https://www.wikidata.org/wiki/Q104837","display_name":"Phase (matter)","level":2,"score":0.5316126346588135},{"id":"https://openalex.org/C2993640289","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Solid tumor","level":3,"score":0.4471901059150696},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.3798902630805969},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3390105962753296},{"id":"https://openalex.org/C192562407","wikidata":"https://www.wikidata.org/wiki/Q228736","display_name":"Materials science","level":0,"score":0.25530505180358887},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.2379205822944641},{"id":"https://openalex.org/C2777767877","wikidata":"https://www.wikidata.org/wiki/Q419327","display_name":"Granulocyte colony-stimulating factor","level":3,"score":0.19823405146598816},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.16668838262557983},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.11668074131011963},{"id":"https://openalex.org/C191897082","wikidata":"https://www.wikidata.org/wiki/Q11467","display_name":"Metallurgy","level":1,"score":0.08342984318733215},{"id":"https://openalex.org/C178790620","wikidata":"https://www.wikidata.org/wiki/Q11351","display_name":"Organic chemistry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000069585","descriptor_name":"Filgrastim","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000972","descriptor_name":"Antineoplastic Agents, Phytogenic","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000972","descriptor_name":"Antineoplastic Agents, Phytogenic","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000972","descriptor_name":"Antineoplastic Agents, Phytogenic","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D002851","descriptor_name":"Chromatography, High Pressure Liquid","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012878","descriptor_name":"Skin Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016179","descriptor_name":"Granulocyte Colony-Stimulating Factor","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D017239","descriptor_name":"Paclitaxel","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D017239","descriptor_name":"Paclitaxel","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D017239","descriptor_name":"Paclitaxel","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D017321","descriptor_name":"Clinical Trials, Phase I as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018288","descriptor_name":"Carcinoma, Small Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/00001813-199808000-00006","doi":"https://doi.org/10.1097/00001813-199808000-00006","is_oa":false,"landing_page_url":"https://doi.org/10.1097/00001813-199808000-00006","pdf_url":null,"source":{"id":"https://openalex.org/S158028025","display_name":"Anti-Cancer Drugs","issn_l":"0959-4973","issn":["0959-4973","1473-5741"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Drugs","raw_type":"journal-article"},{"id":"pmid:9773805","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9773805","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-cancer drugs","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G251702431","display_name":null,"funder_award_id":"RR00046","funder_id":"https://openalex.org/F4320337375","funder_display_name":"National Center for Research Resources"},{"id":"https://openalex.org/G3230350167","display_name":"Altered Hepatic Disposition of Anionic Drugs-Mechanisms","funder_award_id":"R01GM041935","funder_id":"https://openalex.org/F4320337354","funder_display_name":"National Institute of General Medical Sciences"},{"id":"https://openalex.org/G4137263475","display_name":"General Clinical Research Center","funder_award_id":"M01RR000046","funder_id":"https://openalex.org/F4320337375","funder_display_name":"National Center for Research Resources"}],"funders":[{"id":"https://openalex.org/F4320337354","display_name":"National Institute of General Medical Sciences","ror":"https://ror.org/04q48ey07"},{"id":"https://openalex.org/F4320337375","display_name":"National Center for Research Resources","ror":"https://ror.org/04pw6fb54"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1775148994","https://openalex.org/W2240623839","https://openalex.org/W2313509527","https://openalex.org/W2144679758","https://openalex.org/W309646083","https://openalex.org/W2084898366","https://openalex.org/W2268939434","https://openalex.org/W2041587321","https://openalex.org/W2042449296","https://openalex.org/W2281610295"],"abstract_inverted_index":{"A":[0,134],"phase":[1,32,229],"I":[2,33],"study":[3],"of":[4,83,118,129,136,147,156,164,194,232,255],"a":[5],"96":[6,113,166,236],"h":[7,42,51,90,114,167,237],"paclitaxel":[8,37,54,84,105,120,168,184,210,233,265],"infusion":[9,169],"with":[10,26,67,173,182,238,247],"filgrastim":[11,45,174,239],"support":[12,240],"was":[13,39,79,85,101,143,170],"performed":[14,102],"to":[15],"determine":[16],"the":[17,35,53,116,119,165,192,253],"toxicity,":[18],"maximum-tolerated":[19],"dose":[20,38,82,231],"(MTD)":[21],"and":[22,55,112,154,159,177,225,249],"pharmacokinetics":[23],"in":[24,91,145,216],"patients":[25,123,149],"refractory":[27,68],"solid":[28,69],"tumors.":[29],"In":[30,191,252],"this":[31,127],"trial,":[34],"initial":[36],"140":[40],"mg/m2/96":[41,89,152],"followed":[43],"by":[44,87,103],"(5":[46],"microg/kg/day":[47],"s.c.)":[48],"beginning":[49],"24":[50],"after":[52,115],"continued":[56],"until":[57,94],"granulocyte":[58,178,250],"recovery.":[59],"Cycles":[60],"were":[61,71,124,132,140,180,214],"repeated":[62],"every":[63],"21":[64],"days.":[65],"Patients":[66],"tumors":[70],"eligible;":[72],"however,":[73],"only":[74],"one":[75],"previous":[76],"chemotherapy":[77],"regimen":[78],"allowed.":[80],"The":[81,162,227],"escalated":[86],"20":[88],"subsequent":[92],"cohorts":[93],"dose-limiting":[95],"toxicity":[96,179],"(DLT)":[97],"occurred.":[98],"Pharmacokinetic":[99],"analysis":[100],"quantitating":[104],"concentrations":[106,185],"at":[107,150],"baseline,":[108],"24,":[109],"48,":[110],"72":[111],"start":[117],"infusion.":[121],"Twenty-one":[122],"entered":[125],"into":[126],"trial":[128],"which":[130],"19":[131],"evaluable.":[133],"total":[135],"52":[137],"treatment":[138],"cycles":[139],"administered.":[141],"DLT":[142],"seen":[144],"two":[146],"four":[148],"200":[151],"h,":[153],"consisted":[155],"diarrhea,":[157],"mucositis":[158],"granulocytopenic":[160],"infection.":[161],"MTD":[163],"180":[171,242],"mg/m2":[172],"support.":[175],"Mucosal":[176],"correlated":[181],"steady-state":[183],"(Css)":[186],"greater":[187],"than":[188,202],"0.100":[189],"micromol/l.":[190],"presence":[193,254],"liver":[195,205,260],"function":[196],"test":[197],"1.5":[198],"times":[199],"or":[200],"lower":[201],"normal,":[203],"metastatic":[204,259],"disease":[206,261],"did":[207],"not":[208,263],"alter":[209],"Css.":[211],"Objective":[212],"responses":[213],"observed":[215],"non-small":[217],"cell":[218,222],"lung":[219,223],"cancer,":[220],"small":[221],"cancer":[224],"melanoma.":[226],"recommended":[228],"II":[230],"infused":[234],"over":[235],"is":[241],"mg/m2.":[243],"Paclitaxel":[244],"Css":[245],"correlate":[246],"mucosal":[248],"toxicity.":[251],"normal":[256],"enzymatic":[257],"function,":[258],"does":[262],"affect":[264],"clearance.":[266]},"counts_by_year":[{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}